Supporting Information

Tetramic acid analogues produced by co-culture of *Saccharopolyspora erythraea with Fusarium pallidoroseum*

James Whitt,[†] Suzanne M. Shipley[†], David J. Newman[‡] and Karina M. Zuck[†,*]

[†]SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702

[‡]Natural Products Branch, Developmental Therapeutics Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, P.O. Box B, Frederick, MD, 21702

---

[*]To whom correspondence should be addressed. Tel: (301) 846-5688. FAX: (301) 846-5206. E-mail: zuckk@mail.nih.gov

Table of Contents

S3: ^{1}H NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S4: ^{13}C NMR Spectrum of Compound **1**
150 MHz in DMSO-d_6



S5: COSY NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S6: HSQC NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S7: HMBC NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S8: NOESY NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S9: TROESY NMR Spectrum of Compound **1**
500 MHz in DMSO-d_6



S10: ^{1}H NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S11: ^{13}C NMR Spectrum of Compound **2**
150 MHz in DMSO-d_6



S12: COSY NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S13: HSQC NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S14: HMBC NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S15: NOESY NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S16: TROESY NMR Spectrum of Compound **2**
500 MHz in DMSO-d_6



S17: ^{1}H NMR Spectrum of Compound **3**
500 MHz in DMSO-d_6



S18: ^{13}C NMR Spectrum of Compound **3**
150 MHz in DMSO-d_6



S19: COSY NMR Spectrum of Compound **3**
500 MHz in DMSO-d_6



S20: HSQC NMR Spectrum of Compound **3**
500 MHz in DMSO-d_6



S21: HMBC NMR Spectrum of Compound **3**
500 MHz in DMSO-d_6



S22: NOESY NMR Spectrum of Compound **5**
500 MHz in DMSO-d_6



S23: TROESY NMR Spectrum of Compound **5**
500 MHz in DMSO-d_6



S24: NCI-60 Cell Line Testing Results for Equisetin

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC : D - 772378 / 1	Experiment ID : 1301NS14	Test Type : 08	Units : Molar
Report Date : February 11, 2013	Test Date : January 28, 2013	QNS :	MC :
COMI : 126688	Stain Reagent : SRB Dual-Pass Related	SSPL : 0YAT	

		Log10 Concentration													
	Time	Mean Optical Densities						Percent Growth							
Panel/Cell Line	Zero	Ctrl	-8.7	-7.7	-6.7	-5.7	-4.7	-8.7	-7.7	-6.7	-5.7	-4.7	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.656	2.298	2.442	1.633	1.451	1.331	0.991	109	60	48	41	20	1.44E-7	> 2.00E-5	> 2.00E-5
HL-60(TB)	1.006	3.181	3.237	3.332	3.263	2.925	0.985	103	107	104	88	-2	5.30E-6	1.89E-5	> 2.00E-5
K-562	0.279	2.275	2.389	2.480	2.469	1.988	0.482	106	110	110	86	10	5.93E-6	> 2.00E-5	> 2.00E-5
MOLT-4	0.625	2.425	2.608	2.604	2.608	2.431	0.854	110	110	110	100	13	7.51E-6	> 2.00E-5	> 2.00E-5
RPMI-8226	0.768	2.567	2.578	2.529	2.516	2.010	1.045	101	98	97	69	15	4.52E-6	> 2.00E-5	> 2.00E-5
SR	0.258	1.413	1.349	1.406	1.395	1.204	0.322	94	99	98	82	6	5.23E-6	> 2.00E-5	> 2.00E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.365	1.698	1.698	1.654	1.693	1.474	0.551	100	97	100	83	14	6.04E-6	> 2.00E-5	> 2.00E-5
HOP-62	0.582	1.538	1.515	1.487	1.500	1.450	0.798	98	95	96	91	23	7.91E-6	> 2.00E-5	> 2.00E-5
HOP-92	1.156	1.669	1.554	1.616	1.600	1.516	0.997	78	90	86	70	-14	3.48E-6	1.37E-5	> 2.00E-5
NCI-H226	1.166	2.369	2.318	2.259	2.251	2.216	1.376	96	91	90	87	17	6.84E-6	> 2.00E-5	> 2.00E-5
NCI-H23	0.840	2.442	2.392	2.527	2.606	2.304	1.234	97	105	110	91	25	8.32E-6	> 2.00E-5	> 2.00E-5
NCI-H322M	0.668	1.541	1.617	1.640	1.676	1.656	0.807	109	111	115	113	16	8.92E-6	> 2.00E-5	> 2.00E-5
NCI-H460	0.344	2.986	3.092	2.995	3.028	2.601	0.450	104	100	102	85	4	5.45E-6	> 2.00E-5	> 2.00E-5
NCI-H522	0.881	2.278	2.244	2.362	2.349	2.218	0.884	98	106	105	96	.	6.02E-6	> 2.00E-5	> 2.00E-5
Colon Cancer															
COLO 205	0.395	1.654	1.789	1.760	1.799	1.600	0.448	111	108	112	96	4	6.32E-6	> 2.00E-5	> 2.00E-5
HCC-2998	1.107	3.286	3.287	3.378	3.247	3.270	0.987	100	104	98	99	-11	5.60E-6	1.59E-5	> 2.00E-5
HCT-116	0.197	1.621	1.691	1.732	1.739	1.451	0.244	105	108	108	88	3	5.62E-6	> 2.00E-5	> 2.00E-5
HCT-15	0.296	1.690	1.602	1.467	1.501	1.333	0.344	94	84	86	74	3	4.41E-6	> 2.00E-5	> 2.00E-5
HT29	0.342	1.701	1.654	1.740	1.725	1.524	0.470	97	103	102	87	9	6.00E-6	> 2.00E-5	> 2.00E-5
KM12	0.495	2.429	2.465	2.472	2.501	2.150	0.743	102	102	104	86	13	6.16E-6	> 2.00E-5	> 2.00E-5
SW-620	0.322	1.871	1.846	1.823	1.836	1.731	0.534	98	97	98	91	14	6.77E-6	> 2.00E-5	> 2.00E-5
CNS Cancer															
SF-268	0.473	1.683	1.633	1.670	1.661	1.538	0.782	96	99	98	88	26	8.11E-6	> 2.00E-5	> 2.00E-5
SF-539	0.838	2.619	2.512	2.404	2.477	2.455	1.121	94	88	92	91	16	7.01E-6	> 2.00E-5	> 2.00E-5
SNB-19	0.664	2.042	1.929	1.868	1.928	1.718	0.912	92	87	92	76	18	5.67E-6	> 2.00E-5	> 2.00E-5
SNB-75	0.961	1.546	1.407	1.387	1.450	1.433	1.119	76	73	84	81	27	7.45E-6	> 2.00E-5	> 2.00E-5
U251	0.660	2.567	2.453	2.422	2.452	2.165	0.878	94	92	94	79	11	5.36E-6	> 2.00E-5	> 2.00E-5
Melanoma															
LOX IMVI	0.470	2.868	2.723	2.859	2.758	2.696	1.091	94	100	95	93	26	8.72E-6	> 2.00E-5	> 2.00E-5
MALME-3M	0.869	1.716	1.681	1.740	1.699	1.648	1.071	96	103	98	92	24	8.25E-6	> 2.00E-5	> 2.00E-5
M14	0.558	2.156	2.234	2.229	2.182	1.933	0.581	105	105	102	86	1	5.34E-6	> 2.00E-5	> 2.00E-5
SK-MEL-2	1.124	2.004	2.097	2.088	2.171	2.186	1.170	111	110	119	121	5	8.19E-6	> 2.00E-5	> 2.00E-5
SK-MEL-28	0.705	1.886	1.842	1.790	1.854	1.698	0.892	96	92	97	84	16	6.31E-6	> 2.00E-5	> 2.00E-5
SK-MEL-5	0.884	2.758	2.766	2.688	2.688	2.490	0.836	100	96	96	86	-5	4.92E-6	1.74E-5	> 2.00E-5
UACC-257	1.128	2.297	2.242	2.218	2.243	2.293	1.245	95	93	95	100	10	7.16E-6	> 2.00E-5	> 2.00E-5
UACC-62	0.905	2.518	2.470	2.343	2.447	2.157	0.685	97	89	96	78	-24	3.73E-6	1.15E-5	> 2.00E-5
Ovarian Cancer															
IGROV1	0.630	1.682	1.749	1.683	1.781	1.659	0.807	106	100	109	98	17	7.78E-6	> 2.00E-5	> 2.00E-5
OVCAR-3	0.518	1.653	1.709	1.750	1.681	1.353	0.587	105	109	103	74	6	4.47E-6	> 2.00E-5	> 2.00E-5
OVCAR-4	0.596	1.144	1.159	1.097	1.157	0.980	0.583	103	91	102	70	-2	3.80E-6	1.87E-5	> 2.00E-5
OVCAR-5	0.539	1.897	1.827	1.818	1.717	1.667	0.908	95	94	87	83	27	7.80E-6	> 2.00E-5	> 2.00E-5
OVCAR-8	0.468	2.026	1.964	1.979	1.996	1.663	0.556	96	97	98	77	6	4.75E-6	> 2.00E-5	> 2.00E-5
NCI/ADR-RES	0.686	2.385	2.242	2.410	2.454	2.250	0.812	92	101	104	92	7	6.28E-6	> 2.00E-5	> 2.00E-5
SK-OV-3	0.776	1.651	1.709	1.724	1.694	1.738	0.883	107	108	105	110	12	8.22E-6	> 2.00E-5	> 2.00E-5
Renal Cancer															
786-0	0.568	2.352	2.286	2.304	2.327	2.213	0.893	96	97	99	92	18	7.43E-6	> 2.00E-5	> 2.00E-5
A498	1.632	2.496	2.464	2.346	2.376	2.400	1.682	96	83	86	89	6	5.88E-6	> 2.00E-5	> 2.00E-5
ACHN	0.366	1.792	1.799	1.756	1.695	1.601	0.471	101	97	93	87	7	5.79E-6	> 2.00E-5	> 2.00E-5
RXF 393	0.803	1.327	1.297	1.294	1.303	1.261	0.828	94	94	95	87	5	5.67E-6	> 2.00E-5	> 2.00E-5
SN12C	0.700	2.460	2.250	2.218	2.224	2.000	0.858	88	86	87	74	9	4.67E-6	> 2.00E-5	> 2.00E-5
TK-10	0.753	1.664	1.618	1.668	1.711	1.627	0.894	95	100	105	96	15	7.44E-6	> 2.00E-5	> 2.00E-5
UO-31	0.938	2.074	1.949	1.989	1.971	1.868	0.981	89	92	91	82	4	5.11E-6	> 2.00E-5	> 2.00E-5
Prostate Cancer															
PC-3	0.538	2.126	2.105	2.047	2.056	1.604	0.647	99	95	96	67	7	3.85E-6	> 2.00E-5	> 2.00E-5
DU-145	0.393	1.574	1.672	1.654	1.691	1.501	0.678	108	107	110	94	24	8.50E-6	> 2.00E-5	> 2.00E-5
Breast Cancer															
MCF7	0.469	2.411	2.235	2.227	2.277	1.781	0.588	91	91	93	68	6	3.86E-6	> 2.00E-5	> 2.00E-5
MDA-MB-231/ATCC	0.665	1.562	1.553	1.463	1.510	1.541	0.759	99	89	94	98	10	7.04E-6	> 2.00E-5	> 2.00E-5
HS 578T	1.134	2.077	1.975	1.930	1.971	1.919	1.358	89	84	89	83	24	7.24E-6	> 2.00E-5	> 2.00E-5
BT-549	0.955	1.905	1.915	1.949	1.888	1.904	1.096	101	105	98	100	15	7.72E-6	> 2.00E-5	> 2.00E-5
T-47D	1.178	2.137	2.117	2.102	2.135	2.082	1.075	98	96	100	94	-9	5.38E-6	1.64E-5	> 2.00E-5
MDA-MB-468	0.878	1.774	1.710	1.673	1.681	1.333	0.780	93	89	90	51	-11	2.06E-6	1.32E-5	> 2.00E-5

S25: CD Spectra of Compounds **1-3** and Ophiosetin Compared to Equisetin